Tropisetron: Difference between revisions
Kiran Singh (talk | contribs) No edit summary |
Kiran Singh (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{drugbox | | {{drugbox | | ||
| IUPAC_name = [(1''S'',5''S'')-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 1''H''-indole-3-carboxylate | | IUPAC_name = [(1''S'',5''S'')-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 1''H''-indole-3-carboxylate | ||
| image = | | image =Tropisetron2DACS2.png | ||
| image2 = | | image2 =Tropisetron3Dan.gif | ||
| width = 200px | | width = 200px | ||
| CAS_number = 89565-68-4 | | CAS_number = 89565-68-4 | ||
Latest revision as of 15:39, 10 April 2015
 | |
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral, IM |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | ~60–80% |
| Protein binding | 71% |
| Metabolism | Hepatic (CYP3A4, CYP1A2, CYP2D6) |
| Elimination half-life | 6–8 hours |
| Excretion | Renal, Fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C17H20N2O2 |
| Molar mass | 284.353 g/mol |
| 3D model (JSmol) | |
| |
|
WikiDoc Resources for Tropisetron |
|
Articles |
|---|
|
Most recent articles on Tropisetron Most cited articles on Tropisetron |
|
Media |
|
Powerpoint slides on Tropisetron |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tropisetron at Clinical Trials.gov Clinical Trials on Tropisetron at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tropisetron
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tropisetron Discussion groups on Tropisetron Patient Handouts on Tropisetron Directions to Hospitals Treating Tropisetron Risk calculators and risk factors for Tropisetron
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tropisetron |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Tropisetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.[1] The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia and New Zealand as Navoban, but is not available in the U.S.
Adverse effects
Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.
External links
References
- ↑ Muller, W. (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scand J Rheumatic Suppl. 119: 44–48. PMID 15515413. Retrieved 2007-05-17. Unknown parameter
|coauthors=ignored (help)
- Pages with script errors
- Pages with citations using unsupported parameters
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antiemetics
- 5-HT3 antagonists
- Tropanes
- Drugs